CTLA4 and neoplasm: Interestingly, the increase in TIL growth was more profound when using tumor fragments from patients not pre-treated with anti-CTLA-4 antibody before TIL therapy compared to those pre-treated (Table 1, Trial Number NCT02482090 and NCT03287674).